Abstract
Thyroid cancer (TC) is the most common cancer of the endocrine system and is subdivided into four entities: papillary, follicular, medullary, and anaplastic thyroid cancer. Among these, anaplastic thyroid cancer has the poorest prognosis. Exploring new therapeutic approaches is essential for improving predictions and overall survival rates. Long non-coding RNAs (lncRNAs) have vast implications in various cancers; although not transcribed into proteins, they act as harnesses regulating a plethora of biological functions and play a decisive role in gene expression. This article discusses the multi-faceted role of lncRNAs in thyroid cancer biology.
Introduction
Thyroid cancer incidence has risen globally, with annual increases in the US ranging from 2.4% to 6.6%. While many forms are manageable, aggressive variants like anaplastic thyroid cancer remain lethal. The search for precise molecular tools for diagnosis and treatment has led researchers to the "non-coding" genome. Once dismissed as "junk DNA," long non-coding RNAs (lncRNAs)—transcripts longer than 200 nucleotides—are now recognized as master regulators of cellular pathways driving malignancy.
Mechanisms of Gene Regulation
lncRNAs function as molecular scaffolds or "harnesses" that modulate gene expression at multiple levels. One prominent mechanism is the Competitive Endogenous RNA (ceRNA) hypothesis, where lncRNAs act as "sponges" for microRNAs. For instance, the lncRNA NEAT1 sponges miR-129-5p, preventing it from inhibiting the oncogene KLK7, thereby accelerating cancer growth.
As illustrated in the figure above, lncRNAs influence epigenetic regulation (e.g., X-chromosome inactivation), basal and gene-specific transcription, and post-transcriptional processes such as splicing and translation.
Functional Impact on Cancer Hallmarks
Research synthesized from genome-wide association studies (GWAS) and functional assays in cell lines and animal models has identified several "heavy hitter" lncRNAs that dictate thyroid cancer progression. These molecules can either promote oncogenic activity or act as tumor suppressors.
Key findings include:
- HOTAIR: Linked to decreased overall survival in papillary thyroid cancer (PTC), modulating the cell cycle via the miR-1/CCND2 axis.
- MALAT1 & BANCR: Orchestrate the Epithelial-Mesenchymal Transition (EMT), enabling stationary cancer cells to become invasive. MALAT1 also promotes angiogenesis by interacting with FGF2.
- H19: Silencing this lncRNA reduces the "stemness" of cancer cells, potentially increasing treatment sensitivity.
- Diagnostic Synergy: Combining lncRNA detection (e.g., NONHSAT076754) with traditional ultrasonography significantly improves the accuracy of lymph node metastasis prediction.
Conclusion and Future Directions
While the identification of lncRNA signatures offers promising diagnostic and therapeutic avenues, several hurdles remain. Most evidence currently stems from laboratory models, and transitioning to human therapies—such as using small interfering RNA (siRNA) to silence oncogenic lncRNAs—requires overcoming significant clinical and regulatory barriers. Furthermore, the exact "cis" and "trans" mechanisms of many lncRNAs are still being unraveled to ensure high specificity and minimal off-target effects in clinical applications.
Summary updated